Skip to main content
. 2024 Apr 4;14(4):476. doi: 10.3390/life14040476

Figure 2.

Figure 2

Color fundus photographs and optical coherence tomograms of representative cases of successful and failed switches to faricimab. (A) Case without polypoid lesions before switching (best-corrected visual acuity (BCVA) 20/25, dosing interval before switch was 5 weeks). (B) Images in case A at the first visit (5 weeks) after switching (BCVA 20/20). The dosing interval was eventually extended to 7 weeks at 6 months. (C) Case with polypoid lesions before switching (BCVA 20/40, dosing interval before switch was 6 weeks). (D) Images in case C after switching (BCVA 20/32, dosing interval 6 weeks). Early recurrence of subretinal fluid was observed after the switch, and the patient was eventually switched back to aflibercept.